Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H ( (HK:1558) ).
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. successfully held its Annual General Meeting (AGM) on May 29, 2025, where all proposed resolutions were approved by shareholders. The resolutions included the approval of the company’s financial statements and reports for the year ended December 31, 2024, and the re-appointment of KPMG as the company’s auditor. The approval of these resolutions reflects strong shareholder support and positions the company for continued stability and growth.
The most recent analyst rating on (HK:1558) stock is a Buy with a HK$13.80 price target. To see the full list of analyst forecasts on YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H stock, see the HK:1558 Stock Forecast page.
More about YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. is a pharmaceutical company based in the People’s Republic of China. The company is involved in the production and distribution of pharmaceutical products, focusing on providing healthcare solutions.
Average Trading Volume: 6,545,967
Technical Sentiment Signal: Buy
Current Market Cap: HK$13.09B
See more insights into 1558 stock on TipRanks’ Stock Analysis page.